EBITDA Margin % is calculated as EBITDA divided by its Revenue. Surmodics's EBITDA for the
three
months ended in Jun. 2025 was $-3.0 Mil. Surmodics's Revenue for the
three
months ended in Jun. 2025 was $29.6 Mil. Therefore, Surmodics's EBITDA margin for the quarter that ended in Jun. 2025 was -10.02%.
Surmodics (NAS:SRDX) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Surmodics EBITDA Margin % Related Terms
Surmodics EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Surmodics's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SRDX vs CBLL, OFIX, LAB: EBITDA Margin % Comparison
For the Medical Devices subindustry, Surmodics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Surmodics EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Surmodics's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Surmodics's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Surmodics (SRDX) has a EBITDA Margin % of -10.02% as of Jun. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Surmodics and its competitors.
Is Surmodics' EBITDA Margin % too high?
Surmodics' current EBITDA Margin % is -10.02%. Overall, Surmodics has a GF Score™ of 51/100, reflecting its overall financial health beyond just this single metric.
How does Surmodics' EBITDA Margin % compare to CBLL and OFIX?
Surmodics' EBITDA Margin % of -10.02% can be compared against companies in the Medical Devices & Instruments industry. The industry median EBITDA Margin % is 7.48. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.48, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Surmodics and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Surmodics's current EBITDA Margin % is -10.02%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Surmodics stock overvalued right now?
Surmodics (SRDX) has a current EBITDA Margin % of -10.02%. The stock's GF Value™ is $32.10, compared to a current price of $42.98 — trading 33.9% above its estimated fair value. The current EBITDA Margin % is -10.02%. Surmodics' overall GF Score™ is 51/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Surmodics (SRDX), the current EBITDA Margin % is -10.02% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Surmodics (SRDX) Overvalued in 2026?
Based on GuruFocus' analysis, Surmodics stock appears to be overvalued.
The current stock price of $42.98 is trading 33.9% above its estimated GF Value™ of $32.10.
Key valuation signals for SRDX:
EBITDA Margin %: -10.02%
GF Value™: $32.10 vs. price of $42.98 (33.9% above fair value)
No single metric tells the full story. See the SRDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Surmodics Inc is a provider of performance coating technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic (IVD) immunoassay tests and microarrays. The company's reportable segments are; Medical Device and In Vitro Diagnostics. Maximum revenue for the company is derived from its Medical Device segment which is involved in the manufacturing and licensing of performance coatings, including surface modification coating technologies and drug-delivery coating technologies. This segment also manufactures vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. Geographically, the company derives key revenue from its domestic market.
51GF Score
Get the complete analysis for SRDX
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SRDX has been successfully added to your 
